Guobang Pharma Ltd.
SHH: 605507.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Shixue Liao
- Employees
- 4,003
- Headquarters
- Xinchang, China
- IPO year
- 2021
- Market cap
- CN¥12.9B
- Website
- https://www.gbgcn.com
Loading 605507…
Loading profile data…Frequently asked questions about 605507
What does Guobang Pharma Ltd. (605507.SS) do?
Guobang Pharma Ltd. engages in the research and development, production, and sale of medical products for human and animals in China. It offers medical products, including APIs, medication intermediates related to the API, and formulations; and veterinary products, such as APIs for animals, additives, and formulations. The company was founded in...
Where does 605507.SS trade?
Guobang Pharma Ltd. (605507.SS) trades on the Shanghai Stock Exchange.
What sector is 605507.SS in?
Guobang Pharma Ltd. (605507.SS) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Guobang Pharma Ltd.?
Shixue Liao is the chief executive officer of Guobang Pharma Ltd. (605507.SS).
Where is Guobang Pharma Ltd. headquartered?
Guobang Pharma Ltd. is headquartered in China.
Does 605507.SS pay a dividend?
Yes — Guobang Pharma Ltd. (605507.SS) paid a trailing twelve-month dividend of CNY 0.61 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 605507.SS go public?
Guobang Pharma Ltd. (605507.SS) completed its initial public offering in 2021.